Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Teshima T, et al. Among authors: miyamura k. Int J Hematol. 2024 Jul;120(1):106-116. doi: 10.1007/s12185-024-03772-6. Epub 2024 May 25. Int J Hematol. 2024. PMID: 38796666 Free PMC article. Clinical Trial.
Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.
Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, Tanaka J, Ohashi K, Taniguchi S, Ikeda T, Eto T, Mori M, Yamaoka M, Ozawa K. Muroi K, et al. Among authors: miyamura k. Int J Hematol. 2016 Feb;103(2):243-50. doi: 10.1007/s12185-015-1915-9. Epub 2015 Nov 25. Int J Hematol. 2016. PMID: 26608364 Clinical Trial.
Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype.
Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y, Oba T, Miyamura K, Kodera Y, Naoe T. Sugimoto K, et al. Among authors: miyamura k. Int J Hematol. 2008 Jun;87(5):451-458. doi: 10.1007/s12185-008-0061-z. Epub 2008 Mar 26. Int J Hematol. 2008. PMID: 18365141
Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.
Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, Taniguchi S, Imamura M, Ando K, Kato S, Mori T, Teshima T, Mori M, Ozawa K. Muroi K, et al. Among authors: miyamura k. Int J Hematol. 2013 Aug;98(2):206-13. doi: 10.1007/s12185-013-1399-4. Epub 2013 Jul 17. Int J Hematol. 2013. PMID: 23860964 Clinical Trial.
A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.
Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, Kashiwase K, Morishima Y, Fukuda T, Kodera Y, Doki N, Miyamura K, Mori T, Nakao S, Ohtake S, Morishita E. Nomoto H, et al. Among authors: miyamura k. Int J Hematol. 2015 Oct;102(4):460-70. doi: 10.1007/s12185-015-1852-7. Epub 2015 Aug 6. Int J Hematol. 2015. PMID: 26246110 Clinical Trial.
Erratum to: A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.
Nomoto H, Takami A, Espinoza JL, Matsuo K, Mizuno S, Onizuka M, Kashiwase K, Morishima Y, Fukuda T, Kodera Y, Doki N, Miyamura K, Mori T, Nakao S, Ohtake S, Morishita E. Nomoto H, et al. Among authors: miyamura k. Int J Hematol. 2015 Oct;102(4):507-8. doi: 10.1007/s12185-015-1867-0. Int J Hematol. 2015. PMID: 26351240 No abstract available.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection.
Kuwatsuka Y, Atsuta Y, Hirakawa A, Uchida N, Inamoto Y, Najima Y, Ikegame K, Eto T, Ozawa Y, Ichinohe T, Inoue M, Kimura T, Okamoto S, Miyamura K, Fukuda T. Kuwatsuka Y, et al. Among authors: miyamura k. Int J Hematol. 2020 Dec;112(6):841-850. doi: 10.1007/s12185-020-02972-0. Epub 2020 Sep 1. Int J Hematol. 2020. PMID: 32875487
432 results